Onkos Surgical has announced FDA 510(k) clearance of its modular collar portfolio to address implant loosening in orthopedic oncology and complex revision surgery, according to a press release.
The portfolio, which features the company’s BioGrip 3D-printed porous implant technology, is designed to help support bone ingrowth in oncology and complex limb salvage cases.
According to Patrick Treacy, CEO and co-founder of Onkos Surgical “In the past 6 months, we have made significant progress by launching new Eleos products aimed at improving the challenges of soft tissue attachment. Our latest innovation, the BioGrip collar portfolio, delivers on our promise to help address the challenge of implant loosening. With our focused commercial approach and substantial [research and development] investments, we will continue to be the leading provider of innovative solutions for musculoskeletal oncology and other complex orthopedic procedures”.